Chertow B S, Sivitz W I, Baranetsky N G, Styer T B, Sorensen B J, Schikman C H, Norris R M, Ozuk B A
Acta Vitaminol Enzymol. 1982;4(4):291-8.
We tested retinyl palmitate for in vivo effects in man and in vitro effects on the IM-9 lymphocyte insulin receptor. Intravenous glucose tolerance tests (IVGTT) with 25 g glucose were performed on 10 healthy subjects before and after two intramuscular injections of retinyl palmitate (25,000 IU) 18 hours apart. In 9 of 10 subjects, glucose disposition was impaired after treatment with retinyl palmitate. In vitro, retinyl palmitate 10(-4) - 10(-6) M did not affect the binding or displacement of insulin 125I from lymphocyte receptors. We conclude that retinyl palmitate decreases glucose tolerance without demonstrable effects on insulin release or insulin binding to receptors.
我们测试了棕榈酸视黄酯对人体的体内作用以及对IM - 9淋巴细胞胰岛素受体的体外作用。对10名健康受试者进行了两次间隔18小时的肌肉注射棕榈酸视黄酯（25,000国际单位），并在注射前后进行了25克葡萄糖的静脉葡萄糖耐量试验（IVGTT）。在10名受试者中的9名中，棕榈酸视黄酯治疗后葡萄糖处置受损。在体外，10(-4) - 10(-6)M的棕榈酸视黄酯不影响胰岛素125I与淋巴细胞受体的结合或置换。我们得出结论，棕榈酸视黄酯会降低葡萄糖耐量，而对胰岛素释放或胰岛素与受体的结合没有明显影响。
